GMMMG logo

NHS photos

NHS logo

News

<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during July 2017

July 2017

 

High Cost Drugs Subgroup (HCDSG)

25.7.17

On behalf of the GMMMG High Cost Drugs Subgroup, the following Blueteq forms for transition from paediatric (NHSE commissioned) to adult (CCG commissioned) for JIA for 

  • Abatacept
  • Adalimumab
  • Anakinra
  • Etanercept
  • infliximab
  • Rituximab
  • Tocilizumab

    [All document links removed - consultation closed]

have been developed for use across GM.

We now seek comments [Link removed - consultation closed] from GM NHS healthcare professionals on the content of these forms. This consultation period is open until 5:00pm on 9th August 2017. Comments will be considered by the GMMMG High Cost Drugs Subgroup prior to a final draft form being approved for use.

The Pharmaceutical Industry is invited to comment on factual inaccuracies only.

Pathways and Guidelines Development Subgroup (PaGDSG)

21.7.17

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, the following Shared Care Guidelines for DMARDs in Rheumatology are in development following updated drug monitoring guidelines in January 2017 from the British Society of Rheumatology:

  • Azathioprine
  • Ciclosporin
  • Hydroxychloroquine
  • Leflunomide
  • Methotrexate (oral)
  • Mycophenolate
  • Sodium Aurothiomalate
  • Sulfasalazine

We now seek the comments of all GM NHS healthcare professionals on these drafts. This consultation period is open until 5:00pm on Friday 1st September 2017. Links to the documents and associated comments forms are available here [Link removed - consultation closed]. After this period the documents will be reviewed, amended as required and then taken to GMMMG for final approval. The Pharmaceutical Industry is invited to comment on factual inaccuracies only.

20.7.17

A Greater Manchester antimicrobial guideline [Link removed - consultation closed] has been developed in conjunction with  GM CCGs and Public Health England North West technical guidelines group.

The  format and content is based on PHE management of infection guidance for primary care, May 2017 and the Greater Manchester drug options consultation, Jan 2017.

Draft NICE guidance: Sinusitis(acute): antimicrobial prescribing has also been considered. We now seek the comments of all GM NHS healthcare professionals. This consultation period is open until 5pm Friday 28th July 2017. Comments should be submitted here [Link removed - consultation closed]. Industry are invited to comment on factual inaccuracies only.

18.7.17

The Greater Manchester COPD Management Plan and pharmacological treatment pathway [Link removed - consultation closed] has been updated by GM NHS respiratory healthcare professionals with the support of GMMMG. This pathway is intended for use in COPD patients under the care of the Greater Manchester health economy and we now seek the comments of all GM NHS healthcare professionals. This consultation period is open until 5pm Friday 4th August 2017. Comments should be submitted here.[Link removed - consultation closed] Industry are invited to comment on factual inaccuracies only.

Further supporting materials and an updated reference list will be provided.

17.7.17

Agenda for July 2017 meeting, plus the minutes of May 2017 meeting of Pathways and Guidelines Development Subgroup have now been published and are available on site.

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer